Journal
HAEMOPHILIA
Volume 12, Issue 3, Pages 280-284Publisher
WILEY
DOI: 10.1111/j.1365-2516.2006.01212.x
Keywords
acquired haemophilia; alloimmune FVIII antibody; haemophilia A; immune tolerance induction; rituximab
Categories
Ask authors/readers for more resources
We report the use of rituximab (MabThera((R)); Roche Grenzach-Wyhlen, Germany) in a 6-year-old boy with severe haemophilia A and a high titre alloimmune factor VIII (FVIII) antibody, which had failed to respond to standard immune tolerance therapy. Rituximab was administered in 4 weekly doses with concurrent high-dose i.v. immunoglobulin (Flebogamma((R)); Grifols, Barcelona, Spain) followed by daily high-dose recombinant FVIII concentrate (Recombinate((R)); Baxter, CA, USA). Despite a fall in CD20 positive cell count to undetectable levels the inhibitor persisted. We discuss the possible reasons for failure of immune tolerance induction and review the literature concerning the use of rituximab for this indication.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available